{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:59:19Z","timestamp":1763348359928,"version":"build-2065373602"},"reference-count":77,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Otolaryngologic Clinics of North America"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.otc.2021.01.007","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T02:18:26Z","timestamp":1621563506000},"page":"613-627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Molecular Markers that Matter in Salivary Malignancy"],"prefix":"10.1016","volume":"54","author":[{"given":"Katherine C.","family":"Wai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunseok","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick K.","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.otc.2021.01.007_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12105-017-0795-0","article-title":"Update from the 4th edition of the world health organization classification of head and neck tumours: tumors of the salivary gland","volume":"11","author":"Seethala","year":"2017","journal-title":"Head Neck Pathol"},{"issue":"4","key":"10.1016\/j.otc.2021.01.007_bib3","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.rpor.2018.05.004","article-title":"Patterns of treatment failure in salivary gland cancers","volume":"23","author":"Szewczyk","year":"2018","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.otc.2021.01.007_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1758-3284-4-19","article-title":"Systemic therapy in the management of metastatic or advanced salivary gland cancers","volume":"4","author":"Lagha","year":"2012","journal-title":"Head Neck Oncol"},{"key":"10.1016\/j.otc.2021.01.007_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.oraloncology.2017.02.018","article-title":"New concepts of personalized therapy in salivary gland carcinomas","volume":"68","author":"Keller","year":"2017","journal-title":"Oral Oncol"},{"issue":"1","key":"10.1016\/j.otc.2021.01.007_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/hed.25468","article-title":"Salivary gland tumors: molecular characterization and therapeutic advances for metastatic disease","volume":"41","author":"Schvartsman","year":"2019","journal-title":"Head Neck"},{"issue":"5","key":"10.1016\/j.otc.2021.01.007_bib7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/13543784.2019.1598376","article-title":"Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?","volume":"28","author":"Cavalieri","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"10.1016\/j.otc.2021.01.007_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.otc.2021.01.007_bib9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7150\/ijbs.6087","article-title":"The C-kit receptor-mediated signal transduction and tumor-related diseases","volume":"9","author":"Liang","year":"2013","journal-title":"Int J Biol Sci"},{"issue":"1","key":"10.1016\/j.otc.2021.01.007_bib10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3835(00)00387-6","article-title":"Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma","volume":"154","author":"Jeng","year":"2000","journal-title":"Cancer Lett"},{"issue":"3","key":"10.1016\/j.otc.2021.01.007_bib11","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2005.06.125","article-title":"Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a princess margaret hospital phase II consortium study","volume":"23","author":"Hotte","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.otc.2021.01.007_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.oraloncology.2005.12.026","article-title":"A\u00a0phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands","volume":"43","author":"Pfeffer","year":"2007","journal-title":"Oral Oncol"},{"issue":"7","key":"10.1016\/j.otc.2021.01.007_bib13","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.bjoms.2010.09.013","article-title":"Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma","volume":"49","author":"Ghosal","year":"2011","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"2","key":"10.1016\/j.otc.2021.01.007_bib14","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/annonc\/mdv537","article-title":"Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors","volume":"27","author":"Wong","year":"2016","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.otc.2021.01.007_bib15","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.otc.2021.01.007_bib16","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.oraloncology.2008.07.010","article-title":"Cetuximab in recurrent and\/or metastatic salivary gland carcinomas: a phase II study","volume":"45","author":"Locati","year":"2009","journal-title":"Oral Oncol"},{"issue":"5","key":"10.1016\/j.otc.2021.01.007_bib17","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hed.23647","article-title":"Phase II study of gefitinib in patients with advanced salivary gland cancers","volume":"37","author":"Jakob","year":"2015","journal-title":"Head Neck"},{"issue":"25","key":"10.1016\/j.otc.2021.01.007_bib18","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2007.11.8612","article-title":"Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and\/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands","volume":"25","author":"Agulnik","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.otc.2021.01.007_bib19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/PAT.0b013e3283484a60","article-title":"Human epidermal growth factor receptor 2 (HER2) in salivary gland carcinomas","volume":"43","author":"Clauditz","year":"2011","journal-title":"Pathology"},{"issue":"7","key":"10.1016\/j.otc.2021.01.007_bib20","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1368-8375(03)00097-6","article-title":"Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study","volume":"39","author":"Haddad","year":"2003","journal-title":"Oral Oncol"},{"issue":"3","key":"10.1016\/j.otc.2021.01.007_bib21","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1002\/hed.24634","article-title":"Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature","volume":"39","author":"Thorpe","year":"2017","journal-title":"Head Neck"},{"issue":"12","key":"10.1016\/j.otc.2021.01.007_bib22","doi-asserted-by":"crossref","first-page":"E100","DOI":"10.1002\/hed.25392","article-title":"Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas","volume":"40","author":"Park","year":"2018","journal-title":"Head Neck"},{"issue":"7","key":"10.1016\/j.otc.2021.01.007_bib23","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1634\/theoncologist.2019-0841","article-title":"The benefits of adjuvant trastuzumab for HER-2-positive salivary gland cancers","volume":"25","author":"Hanna","year":"2020","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.otc.2021.01.007_bib24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.otc.2021.01.007_bib25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.annonc.2019.11.018","article-title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study","volume":"31","author":"Kurzrock","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.otc.2021.01.007_bib26","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1186\/s12885-019-6132-0","article-title":"Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis","volume":"19","author":"Chen","year":"2019","journal-title":"BMC Cancer"},{"issue":"15_suppl","key":"10.1016\/j.otc.2021.01.007_bib27","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1200\/JCO.2019.37.15_suppl.6001","article-title":"Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): results from a phase II basket trial","volume":"37","author":"Li","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.otc.2021.01.007_bib28","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes Cancer"},{"issue":"2","key":"10.1016\/j.otc.2021.01.007_bib29","doi-asserted-by":"crossref","first-page":"518","DOI":"10.4143\/crt.2015.093","article-title":"VEGF and Ki-67 overexpression in predicting poor overall survival in adenoid cystic carcinoma","volume":"48","author":"Park","year":"2016","journal-title":"Cancer Res Treat"},{"issue":"22","key":"10.1016\/j.otc.2021.01.007_bib30","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","article-title":"Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3","volume":"14","author":"Hu-Lowe","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.otc.2021.01.007_bib31","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdw287","article-title":"A\u00a0phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma","volume":"27","author":"Ho","year":"2016","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.otc.2021.01.007_bib32","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/hed.25891","article-title":"Phase II trial with axitinib in recurrent and\/or metastatic salivary gland cancers of the upper aerodigestive tract","volume":"41","author":"Locati","year":"2019","journal-title":"Head Neck"},{"issue":"15_suppl","key":"10.1016\/j.otc.2021.01.007_bib33","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1200\/JCO.2020.38.15_suppl.6503","article-title":"Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma","volume":"38","author":"Keam","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.otc.2021.01.007_bib34","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/cncr.30537","article-title":"Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: a multicenter phase 2 study (Korean Cancer Study Group HN14-01)","volume":"123","author":"Kim","year":"2017","journal-title":"Cancer"},{"issue":"15_suppl","key":"10.1016\/j.otc.2021.01.007_bib35","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.1200\/JCO.2018.36.15_suppl.6026","article-title":"Phase II trial of apatinib in patients with recurrent and\/or metastatic adenoid cystic carcinoma of the head and neck: Updated analysis","volume":"36","author":"Zhu","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.otc.2021.01.007_bib36","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1172\/JCI67201","article-title":"Whole exome sequencing of adenoid cystic carcinoma","volume":"123","author":"Stephens","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"11","key":"10.1016\/j.otc.2021.01.007_bib37","first-page":"1199","article-title":"Regulation of fibroblast growth factor 2 expression in melanoma cells by the c-MYB proto-oncoprotein","volume":"8","author":"Miglarese","year":"1997","journal-title":"Cell Growth Differ"},{"issue":"10","key":"10.1016\/j.otc.2021.01.007_bib38","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1158\/1078-0432.CCR-04-2129","article-title":"In\u00a0vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models","volume":"11","author":"Lee","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.otc.2021.01.007_bib39","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/cncr.29401","article-title":"Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma","volume":"121","author":"Keam","year":"2015","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.otc.2021.01.007_bib40","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1158\/1078-0432.CCR-16-2942","article-title":"A\u00a0phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma","volume":"23","author":"Dillon","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.otc.2021.01.007_bib41","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.otc.2021.01.007_bib42","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/hed.23577","article-title":"Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck","volume":"37","author":"Thomson","year":"2015","journal-title":"Head Neck"},{"key":"10.1016\/j.otc.2021.01.007_bib43","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2016.09.022","article-title":"A\u00a0phase II study of sorafenib in recurrent and\/or metastatic salivary gland carcinomas: translational analyses and clinical impact","volume":"69","author":"Locati","year":"2016","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.otc.2021.01.007_bib44","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/annonc\/mdr522","article-title":"A\u00a0phase II study of sunitinib in recurrent and\/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC","volume":"23","author":"Chau","year":"2012","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.otc.2021.01.007_bib45","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1634\/theoncologist.2019-0407","article-title":"Lenvatinib in management of solid tumors","volume":"25","author":"Hao","year":"2020","journal-title":"Oncologist"},{"issue":"18","key":"10.1016\/j.otc.2021.01.007_bib46","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.18.01859","article-title":"Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma","volume":"37","author":"Tchekmedyian","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.otc.2021.01.007_bib47","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0b013e3181d9efcc","article-title":"Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity","volume":"34","author":"Sk\u00e1lov\u00e1","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1016\/j.otc.2021.01.007_bib48","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.otc.2021.01.007_bib49","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.otc.2021.01.007_bib50","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.otc.2021.01.007_bib51","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cellsig.2016.01.013","article-title":"The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance","volume":"28","author":"Zarif","year":"2016","journal-title":"Cell Signal"},{"issue":"11","key":"10.1016\/j.otc.2021.01.007_bib52","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/PAS.0b013e3180caa099","article-title":"Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients","volume":"31","author":"Williams","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.otc.2021.01.007_bib53","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/cancers9020017","article-title":"Androgen receptor signaling in salivary gland cancer","volume":"9","author":"Dalin","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.otc.2021.01.007_bib54","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.21873\/anticanres.11196","article-title":"Blockade of androgen-induced malignant phenotypes by flutamide administration in human salivary duct carcinoma cells","volume":"36","author":"Kamata","year":"2016","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.otc.2021.01.007_bib55","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.amjoto.2014.07.007","article-title":"Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy","volume":"35","author":"Yamamoto","year":"2014","journal-title":"Am J Otol"},{"issue":"5","key":"10.1016\/j.otc.2021.01.007_bib56","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jormas.2019.12.012","article-title":"Combined androgen deprivation therapy in recurrent androgen-receptor-positive salivary duct carcinoma - a case report and review of the literature","volume":"121","author":"Poxleitner","year":"2020","journal-title":"J\u00a0Stomatol Oral Maxillofac Surg"},{"issue":"3","key":"10.1016\/j.otc.2021.01.007_bib57","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hed.25035","article-title":"Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands","volume":"40","author":"Boon","year":"2018","journal-title":"Head Neck"},{"issue":"11","key":"10.1016\/j.otc.2021.01.007_bib58","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1002\/ijc.32795","article-title":"Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients","volume":"146","author":"van Boxtel","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.otc.2021.01.007_bib59","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3389\/fonc.2019.00701","article-title":"First line androgen deprivation therapy vs. Chemotherapy for patients with androgen receptor positive recurrent or metastatic salivary gland carcinoma-a retrospective study","volume":"9","author":"Viscuse","year":"2019","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.otc.2021.01.007_bib60","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A\u00a0prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.otc.2021.01.007_bib61","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.1200\/JCO.2019.37.15_suppl.6020","article-title":"Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers","volume":"37","author":"Ho","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.otc.2021.01.007_bib62","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2018.12.035","article-title":"Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma","volume":"110","author":"van Boxtel","year":"2019","journal-title":"Eur J Cancer"},{"issue":"16","key":"10.1016\/j.otc.2021.01.007_bib63","doi-asserted-by":"crossref","first-page":"6885","DOI":"10.18632\/oncotarget.2321","article-title":"NOTCH1 signaling contributes to cell growth, anti-apoptosis and metastasis in salivary adenoid cystic carcinoma","volume":"5","author":"Su","year":"2014","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.otc.2021.01.007_bib64","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JCO.2016.67.5264","article-title":"Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to notch1 inhibitors","volume":"35","author":"Ferrarotto","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.otc.2021.01.007_bib65","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12967-015-0520-2","article-title":"Notch-1 knockdown suppresses proliferation, migration and metastasis of salivary adenoid cystic carcinoma cells","volume":"13","author":"Chen","year":"2015","journal-title":"J\u00a0Transl Med"},{"issue":"2","key":"10.1016\/j.otc.2021.01.007_bib66","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s10637-019-00739-x","article-title":"Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma","volume":"38","author":"Even","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.otc.2021.01.007_bib67","doi-asserted-by":"crossref","unstructured":"Ferrarotto R, Wirth LJ, Muzaffar J, Rodriguez CP, Xia B, Perez CA, Bowles DW, Winquist E, Hotte SJ, Metcalf R, Even C, Gordon GB, Gordon G, Ho A. Annals of Oncology 2020; 31(suppl_4):s599-S628.","DOI":"10.1016\/j.annonc.2020.08.1034"},{"issue":"7","key":"10.1016\/j.otc.2021.01.007_bib68","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.oraloncology.2014.04.003","article-title":"The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck","volume":"50","author":"Zandberg","year":"2014","journal-title":"Oral Oncol"},{"issue":"1","key":"10.1016\/j.otc.2021.01.007_bib69","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jso.24266","article-title":"Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas","volume":"114","author":"Mukaigawa","year":"2016","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.otc.2021.01.007_bib70","first-page":"1","article-title":"Salivary gland cancer in the era of immunotherapy: can we exploit tumor microenvironment?","author":"Theocharis","year":"2020","journal-title":"Expert Opin Ther Targets"},{"issue":"11","key":"10.1016\/j.otc.2021.01.007_bib71","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/COC.0000000000000429","article-title":"Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study","volume":"41","author":"Cohen","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"10.1016\/j.otc.2021.01.007_bib72","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/j.seminoncol.2017.06.002","article-title":"A\u00a0molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab","volume":"44","author":"Fessas","year":"2017","journal-title":"Semin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.otc.2021.01.007_bib73","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1200\/JCO.2019.37.15_suppl.6083","article-title":"NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent\/metastatic (R\/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group","volume":"37","author":"Fayette","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"16 Supplement","key":"10.1016\/j.otc.2021.01.007_bib74","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1158\/1538-7445.AM2020-3418","article-title":"Abstract 3418: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The salivary gland tumor cohort","volume":"80","author":"Chae","year":"2020","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.otc.2021.01.007_bib75","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","article-title":"HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 Blockade","volume":"3","author":"Woods","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.otc.2021.01.007_bib76","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrd772","article-title":"Histone-deacetylase inhibitors: novel drugs for the treatment of cancer","volume":"1","author":"Johnstone","year":"2002","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.otc.2021.01.007_bib77","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/1078-0432.CCR-19-2214","article-title":"A\u00a0phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer","volume":"26","author":"Rodriguez","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.otc.2021.01.007_bib78","doi-asserted-by":"crossref","first-page":"32918","DOI":"10.18632\/oncotarget.16464","article-title":"A\u00a0phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma","volume":"8","author":"Goncalves","year":"2017","journal-title":"Oncotarget"}],"container-title":["Otolaryngologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666521000074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666521000074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T14:53:13Z","timestamp":1758466393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0030666521000074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0030666521000074"],"URL":"https:\/\/doi.org\/10.1016\/j.otc.2021.01.007","relation":{},"ISSN":["0030-6665"],"issn-type":[{"type":"print","value":"0030-6665"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Markers that Matter in Salivary Malignancy","name":"articletitle","label":"Article Title"},{"value":"Otolaryngologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.otc.2021.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}